2026-01-12 - Analysis Report
**English Report**

### 1. Stock Performance Comparison

**Company Overview:** Eli Lilly and Co (LLY) - Pharmaceutical company.

**Return Rates:**

* Review Stock (LLY): 275.77%
* Comparison Stock (VOO): 94.03%

**Divergence Analysis:**
The review stock has a high degree of divergence from the comparison stock, with a current divergence of 181.70.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 37.0% | 14.3% | 33.0% | 0.7  | 103.7B |
| 2017-2019  | 36.0% | 14.7% | 19.0% | 0.7  | 117.8B |
| 2018-2020  | 30.0% | 20.9% | 10.0% | 0.7  | 151.4B |
| 2019-2021  | 49.0% | 20.9% | 5.0%  | 0.7  | 247.6B |
| 2020-2022  | 59.0% | 20.9% | 60.0% | 0.7  | 328.0B |
| 2021-2023  | 116.0% | 18.0% | 115.0% | 0.5  | 522.6B |
| 2022-2024  | 123.0% | 27.0% | 104.0% | 0.6  | 692.1B |
| 2023-2025  | 183.0% | 29.9% | 121.0% | 0.7  | 963.4B |

### 2. Stock Price Fluctuations

* Close: $1,063.56
* Last-Market: $1,063.56 (prev close: $1,085.19, change: -1.99)
* Moving Average (SMA): 
  + 5-day: $1,072.48
  + 20-day: $1,065.11
  + 60-day: $988.30

### 3. RSI, PPO, and Delta Analysis

* Market Risk Indicator (MRI): 0.70 (Medium Investment)
* RSI: 51.73
* PPO: -0.31
* Hybrid Signal: Buy (Cash 0%)
* 20-day relative divergence change: -3.40 (worsening)
* 7-day rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 4.80 (+)
* Expected Return: 52.10% (compared to S&P 500)

### 4. Recent News and Significant Events

* Eli Lilly breaks out after acquiring Ventyx Biosciences for $1.2 billion.
* UBS has a positive view on Eli Lilly and Company (LLY).

### 5. Analyst Opinions

 Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): $1,116.33 / $1,500.00 / $770.00

### 6. Recent Earnings Analysis

| Date | EPS | Revenue |
|-----:|----:|---------|
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3  | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |
| 2025-10-30 | 1.08 | $11.44B |

**Revenue and Profitability Analysis:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91%      |
| 2025-06-30 | $15.56B | 84.27%      |
| 2025-03-31 | $12.73B | 82.53%      |
| 2024-12-31 | $13.53B | 82.24%      |
| 2024-09-30 | $11.44B | 81.02%      |

**Capital and Profitability Analysis:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81%  |

### 7. Comprehensive Analysis (Summary of previous items)

Based on the analysis, Eli Lilly and Co (LLY) is a high-performing stock with a high degree of divergence from the S&P 500. The company has a strong return history, with a cumulative return of 275.77%. The Alpha and Beta analysis shows a consistent performance, with a Beta of 0.7 across the analysis periods. The company's RSI and PPO indicators suggest a medium-risk investment, with a Market Risk Indicator (MRI) of 0.70. The recent news and events highlight the company's positive performance, including the acquisition of Ventyx Biosciences. The analyst opinions are also positive, with a consensus rating of Buy. Overall, Eli Lilly and Co (LLY) appears to be a solid investment opportunity, with a strong track record and growth potential.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.